A Phase II, Open-label, Multicenter, International Study of Durvalumab Following Radiation Therapy in Patients with Stage III, Unresectable Non-Small Cell Lung Cancer Who Are Ineligible for Chemotherapy (DUART)
This is a Phase II open-label, single-arm, multicenter, international study to evaluate the clinical activity of durvalumab in patients with Stage III unresectable NSCLC who are deemed to be ineligible for chemotherapy per Investigator assessment.
Primary Objective: To assess the safety and tolerability profile of durvalumab as defined by Grade 3 and Grade 4 PRAEs within 6 months from the initiation of durvalumab treatment.
Secondary: To assess the efficacy of durvalumab treatment in terms of PFS and OS.
To further assess the efficacy of durvalumab treatment in terms of ORR and DoR.
To assess the efficacy of durvalumab treatment in terms of lung cancer mortality.
To further assess the safety and tolerability profile of durvalumab treatment, including all AEs.
Histologically or cytologically documented NSCLC with locally-advanced, unresectable Stage III disease.
Deemed ineligible for chemotherapy per Investigator assessment.
Receipt of radiation therapy that was completed within 42 days prior to first study drug administration.
Must have received a total dose of radiation of 40 to 66 Gy (standard or hypofractionated BED).
Must not have progressed following radiation therapy, as per Investigator assessed RECIST 1.1 criteria: a) Patients with measurable disease and/or nonmeasurable and/or no evidence of disease assessed at baseline by computed tomography /magnetic resonance imaging will be eligible for this study. b) Prior irradiated lesions may be considered measurable and selected as target lesions (TLs) providing they fulfill the other criteria for measurability.
World Health Organization/ECOG performance status of > No prior exposure to immune-mediated therapy including, but not limited to, anti-CTLA-4, anti-PD-1, anti-PD-L1, and antiprogrammed cell death ligand 2 (anti-PD-L2) antibodies, excluding therapeutic anticancer vaccines.
Patients must have adequate organ and marrow function as defined by protocol
Life expectancy of greater than 12 weeks.
Body weight greater than 30 kg at study entry and at first study drug administration
Patients with locally-advanced NSCLC whose disease has progressed following radiation therapy.
Mixed small cell lung cancer and NSCLC histology.
History of allogeneic organ transplantation.
Active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative, systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome).
Uncontrolled intercurrent illness (e.g., ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris)
History of another primary malignancy except for (a) malignancy treated with curative intent and with no known active disease > 5 years before the first study drug administration, (b) adequately treated nonmelanoma skin cancer or lentigo maligna without evidence of disease, and c) treated carcinoma in situ without evidence of disease.
History of leptomeningeal carcinomatosis
History of active primary immunodeficiency
Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus
Any unresolved toxicity NCI CTCAE Grade > 2 from previous anticancer therapy with the exception of alopecia, vitiligo, lymphopenia, and the laboratory values defined in the inclusion criteria
Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
Receipt of live attenuated vaccine within 30 days prior to the first dose of durvalumab
Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of durvalumab.
Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab.
Participation in another clinical study with an IP administered in the last 4 weeks.
Concurrent enrollment in another clinical study, unless it is an observational (noninterventional) clinical study or during the follow-up period of an interventional study
Prior randomization or treatment in a previous durvalumab clinical study regardless of treatment arm assignment
Patients who refuse chemotherapy by their own decision.
Involvement in the planning and/or conduct of the study
Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control.
Judgment by the Investigator that the patient should not participate in the study
Genetics research study (optional):
Exclusion criteria for participation in the optional genetics research component of the study include: a) Previous allogeneic bone marrow transplant b)Nonleukocyte-depleted whole blood transfusion within 120 days of genetic sample collection.
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub